Cirata (GB:CRTA)
LSE:CRTA
Top Page
Cirata
(LSE:CRTA)
Select Model
Select Model
Rating:54Neutral
Price Target:
22.50 p
▲(7.14% Upside)
Action:ReiteratedDate:12/07/25
Cirata's overall stock score is primarily impacted by its financial challenges, including negative cash flows and profitability issues. However, recent strategic moves and positive corporate events provide some optimism for future growth. Technical indicators and valuation metrics remain weak, tempering the overall outlook.
Positive Factors
Revenue and bookings acceleration
Sustained H1 revenue growth (+40% YoY) and a 58% rise in bookings indicate expanding product adoption and stronger sales momentum in core markets. For a subscription-driven software business, higher bookings improve future recurring revenue visibility and support scaling of margins over the medium term.
Negative Factors
Persistent negative free cash flow
Multi-year negative free cash flow and poor operating-cash-to-income conversion indicate the business is not self-funding growth. Continued dependency on financing risks dilution or constrained investment capacity, limiting the firm's ability to sustainably fund sales, R&D, and go-to-market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and bookings acceleration
Sustained H1 revenue growth (+40% YoY) and a 58% rise in bookings indicate expanding product adoption and stronger sales momentum in core markets. For a subscription-driven software business, higher bookings improve future recurring revenue visibility and support scaling of margins over the medium term.
Read all positive factors
Cirata (CRTA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£16.65M
Dividend YieldN/A
Average Volume (3M)311.29K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth1.65%
EPS Growth29.02%
CountryUK
Employees103
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.04
Shares Outstanding126,340,250
10 Day Avg. Volume624,016
30 Day Avg. Volume311,286
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.62
Price to Sales (P/S)4.52
P/FCF Ratio-2.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£44.00Price Target Upside109.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£11.70M
Cirata Business Overview & Revenue Model
Company Description
Cirata plc, together with its subsidiaries, engages in the development and provision of collaboration software in North America, Europe, China, and internationally. The company's WANdisco Data Activation Platform offers Data Migrator, an automated...
How the Company Makes Money
Wandisco generates revenue primarily through subscription-based licensing of its software products, which provide businesses with the tools necessary for data migration and management. Key revenue streams include annual contracts for its LiveData ...
Cirata Earnings Call Summary
Earnings Call Date:Sep 03, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 09, 2026
Earnings Call Sentiment Neutral
Cirata's earnings call indicates strong revenue and bookings growth, effective cost management, and strategic partnerships, paired with challenges in sales execution and customer acquisition. While there are significant achievements, the need for improved execution in certain areas tempers overall enthusiasm.Positive Updates
Significant Revenue Growth
Revenue for the first half of 2025 rose to $4.8 million, up from $3.4 million a year ago, marking an increase of over 40%.
Negative Updates
Disappointing Q2 Performance
Q2 results were below expectations, failing to demonstrate consistent quarterly progress.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
Revenue for the first half of 2025 rose to $4.8 million, up from $3.4 million a year ago, marking an increase of over 40%.
Read all positive updates
Company Guidance
In the recent call, Cirata reported significant progress in the first half of fiscal year 2025, with revenues rising over 40% to $4.8 million from $3.4 million a year ago, and bookings increasing by 58% to $3.8 million. The company achieved a notable reduction in cash overheads, from $11.8 million to $8.5 million, contributing to the halving of its adjusted EBITDA loss from $8.6 million to $4 million. Cirata ended June with a cash plus receivables position of $7.4 million. The data integration segment, a core focus for Cirata, showed robust growth, with bookings in this area soaring over 200% year-on-year to $3.1 million. Despite a disappointing Q2, the first half data integration bookings were up significantly, and the company successfully signed 20 contracts, including an enterprise-wide license with a top retailer. Strategic moves, such as divesting DevOps assets to BlueOptima, resulted in up to $3.5 million in cash and allowed Cirata to concentrate on its data integration business. Additionally, the appointment of Dominic Arcari as Chief Revenue Officer is expected to enhance sales execution. The outlook remains positive, with expectations of continued triple-digit growth in data integration and no further working capital fundraise needed in FY '25.Cirata Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.46M | 7.68M | 6.70M | 9.69M | 7.31M | 10.53M |
| Gross Profit | 6.75M | 7.14M | 6.06M | 8.99M | 6.65M | 9.47M |
| EBITDA | -9.28M | -14.39M | -36.69M | -39.13M | -32.47M | -33.27M |
| Net Income | -17.52M | -13.51M | -36.48M | -29.61M | -37.59M | -34.33M |
Balance Sheet | ||||||
| Total Assets | 10.36M | 14.92M | 23.11M | 26.54M | 42.19M | 41.32M |
| Cash, Cash Equivalents and Short-Term Investments | 6.08M | 9.73M | 18.25M | 19.11M | 27.76M | 21.04M |
| Total Debt | 749.00K | 889.00K | 795.00K | 539.00K | 1.82M | 2.89M |
| Total Liabilities | 4.94M | 5.35M | 6.50M | 8.64M | 7.76M | 12.12M |
| Stockholders Equity | 5.42M | 9.57M | 16.61M | 16.56M | 34.42M | 29.19M |
Cash Flow | ||||||
| Free Cash Flow | -8.98M | -14.88M | -30.67M | -27.70M | -34.00M | -24.23M |
| Operating Cash Flow | -8.86M | -14.77M | -30.60M | -27.50M | -28.23M | -18.71M |
| Investing Cash Flow | -121.76K | -107.00K | -43.00K | -158.00K | -5.76M | -5.51M |
| Financing Cash Flow | 6.13M | 6.44M | 29.10M | 19.48M | 40.79M | 21.82M |
Cirata Technical Analysis
Negative
21.00
Price Trends
17.25
Negative
18.56
Negative
19.76
Negative
Market Momentum
-0.97
Positive
21.11
Positive
26.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRTA, the sentiment is Negative. The current price of 21 is above the 20-day moving average (MA) of 15.47, above the 50-day MA of 17.25, and above the 200-day MA of 19.76, indicating a bearish trend. The MACD of -0.97 indicates Positive momentum. The RSI at 21.11 is Positive, neither overbought nor oversold. The STOCH value of 26.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRTA.
Cirata Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £79.36M | 54.18 | 2.93% | ― | -3.95% | 16.87% | |
68 Neutral | £93.82M | 20.36 | 11.98% | 0.79% | 12.10% | 27.35% | |
68 Neutral | £174.01M | 37.63 | 5.22% | 0.80% | 22.80% | -32.13% | |
68 Neutral | £140.04M | -33.80 | -2.11% | ― | 31.86% | -115.22% | |
67 Neutral | £137.52M | 11.95 | 8.80% | 1.68% | 6.27% | 0.83% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | £16.65M | -4.22 | -268.88% | ― | 1.65% | 29.02% |
* Technology Sector Average
GB:CRTA
Cirata
13.18
-4.84
-26.89%
GB:ACSO
accesso Technology
245.00
-165.00
-40.24%
GB:DOTD
Dotdigital
45.35
-19.45
-30.02%
GB:ELCO
Eleco
111.50
0.22
0.20%
GB:NET
Netcall
102.00
7.31
7.72%
GB:AOM
ActiveOps plc
196.00
112.50
134.73%
Cirata Corporate Events
Executive/Board Changes
Cirata Grants Performance-Linked Share Options to CTO and CRO
Positive
Feb 4, 2026
Cirata plc has granted new equity-based awards under its Share Options Plan to Chief Technical Officer Paul Scott Murphy and Chief Revenue Officer Dominic Arcari, reflecting the board’s use of long-term incentives to align senior leadership ...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Cirata posts record Data Integration bookings as it refocuses on core data platforms
Positive
Jan 14, 2026
Cirata reported a record finish to FY25, with Data Integration bookings surging 181% year-on-year to $13.2m and Q4 DI bookings hitting an all-time quarterly high of $9.8m, underpinned by the largest direct contract ($3.1m with a leading US insurer...
Business Operations and StrategyM&A Transactions
Cirata Receives Final US$900,000 from BlueOptima for DevOps Asset Sale
Positive
Dec 19, 2025
Cirata plc has received the final consideration payment of US$900,000 from BlueOptima following the completion of the divestment of its DevOps assets, confirming that no further sums are due under the transaction agreed earlier in 2025. The receip...
Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance
Cirata Cleared by FCA, Embarks on New Growth Chapter
Positive
Nov 27, 2025
Cirata plc, a company in the UK tech sector, has announced that the Financial Conduct Authority (FCA) has closed its investigation into the company without taking any action. The investigation, which began in April 2023, focused on whether Cirata ...
Business Operations and Strategy
Cirata Secures Landmark $6.7M Contract with IBM
Positive
Nov 17, 2025
Cirata plc has secured a significant $6.7 million, three-year contract with IBM to provide data integration software for a financial services client. This contract, the largest in Cirata’s history with IBM, is expected to enhance Cirata̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.